Fig. 27.1
Paraneoplastic limbic encephalitis. Coronal Flair images. (a, b) demonstrate first acute phase with swelling and hyperintensity in right insular and mesial temporal lobes; after 3 months, (c) atrophy is clearly observed. In (d, e) a second acute phase with swelling and hyperintensity is seen in the left temporal mesial and partially in the insular lobes. After 3 months, (f) bilateral marked hippocampal atrophy is present
EEG
Non-specific slow disorganized or epileptic activity.
Electromyography (EMG)
Non-length dependent pattern (SSN); decremental response to repetitive nerve stimulation (myasthenia) and post-tetanic potentiation of CMAP (LEMS), peripheral hyperexcitability with fibrillation, and fasciculations (neuromyotonia).
Antibody Screening
The antibodies are associated with clinical syndromes and tumors according to a number of common patterns (see Tables 27.1 and 27.2).
Table 27.1
Onconeural antibodies: association with tumors and PNS
Antibody | Most commonly associated tumors | Syndrome | Antibody positivity without a tumor (%) | Frequency in tumor without PNS (%) |
---|---|---|---|---|
Anti-Hu | SCLC | Encephalomyelitis Limbic encephalitis PCD Brainstem encephalitis Intestinal pseudo-obstruction | 2 | 16 |
Anti-CV2 | SCLC, thymoma | Encephalomyelitis Chorea PCD Limbic encephalitis | 4 | 9 |
Anti-amphiphysin | Breast, SCLC | SPS Myelopathy PEM | 5 | 1 |
Anti-Ri | Breast, SCLC | Brainstem encephalitis Opsoclonus-Myoclonus | 3 | 4 |
Anti-Yo | Ovary, breast | PCD | 2 | 1 |
Anti-Ma2 | Testicle | Limbic encephalitis Brainstem encephalitis | 4 | 0 |
Table 27.2
Antibodies against surface antigens: most common association with tumors and syndromes
Antibody | Syndromes | Most commonly associated tumors | Frequency of paraneoplastic cases |
---|---|---|---|
Anti-LGI1 | Limbic encephalitis | SCLC, thymoma | Rare |
Anti-Caspr2 | Limbic encephalitis, neuromyotonia, Morvan’s syndrome | Thymoma | 40 % |
Anti-NMDAR | Encephalitis | Ovarian teratoma | 6 % in children; 50 % in adults |
Anti-AMPAR | Limbic encephalitis | SCLC, breast, thymoma | 70 % |
Anti-GABAR
Stay updated, free articles. Join our Telegram channelFull access? Get Clinical TreeGet Clinical Tree app for offline access |